A 503A pharmacy compounds medications for individual, patient-specific prescriptions under state board of pharmacy oversight. A 503B outsourcing facility manufactures larger batches of compounded drugs under FDA cGMP rules and can sell office-stock to clinics without a patient name. Both categories are defined by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Key takeaways
503A = patient-specific prescriptions, state-regulated, no cGMP requirement.
503B = FDA-registered outsourcing facilities, cGMP-compliant, may sell office-use stock.
Only 503B facilities can legally ship non-patient-specific bulk orders to clinics.
Both categories were formalized by the Drug Quality and Security Act (DQSA) of 2013 after the NECC meningitis outbreak.
Clinics often use both: 503A for customized patient formulas, 503B for in-office administration.
What is the difference between a 503A and 503B pharmacy?
A 503A is a traditional compounding pharmacy that fills patient-specific prescriptions and is regulated primarily by state boards of pharmacy. A 503B is an FDA-registered outsourcing facility that compounds in larger batches under current Good Manufacturing Practice (cGMP) standards and may distribute office-use stock without individual prescriptions.
Both categories were created by the Drug Quality and Security Act (DQSA) of 2013, passed in direct response to the 2012 New England Compounding Center (NECC) fungal meningitis outbreak that killed 64 patients. 503A is codified at 21 U.S.C. § 353a; the outsourcing facility definition sits at 21 U.S.C. § 353b(d)(4).
FDA is direct about the trade-off. Outsourcing facilities “are inspected by FDA according to a risk-based schedule and are subject to increased quality standards,” and separately, “Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements.” (FDA, Compounding and the FDA: Questions and Answers)
FDA’s register lists 97 outsourcing facilities as of August 4, 2026. That count comes from the register itself — FDA publishes no total on the page. Worth noting for anyone reading it as a market-structure number: at least nine operators hold two listings each, so at most 88 distinct operators sit behind those 97 listings.
The category is growing, not shrinking. FDA’s own end-of-fiscal-year counts run 74 (FY2018), 74 (FY2021), 72 (FY2023), 83 (FY2024), 93 (FY2025), against 97 on the current live list — the highest figure in the series.
A practical comparison:
| Dimension | 503A | 503B |
|---|---|---|
| Regulator | State board of pharmacy | FDA (primary) plus state |
| Patient-specific Rx required | Yes | No |
| cGMP compliance | No | Yes (21 CFR 210/211) |
| Batch size | Small, Rx-driven | Large batches |
| Office-use stock | Generally prohibited | Permitted |
| Inspection cadence | State-driven | FDA risk-based |
503A pharmacies require a valid patient-specific prescription, with limited anticipatory compounding allowed under 503A(a)(2). 503B facilities can compound without prescriptions but only from the FDA bulks list or approved drug ingredients.
One thing neither category does: registration with FDA is not a quality determination, and no compounded drug is FDA-approved regardless of which section it was compounded under.
What are the key regulatory and compliance requirements for 503A vs 503B facilities?
503A pharmacies must follow USP 795 (non-sterile) and USP 797 (sterile) compounding standards plus state pharmacy law, but are exempt from FDA cGMP, new drug approval, and labeling requirements that apply to manufacturers. 503B outsourcing facilities must comply with FDA cGMP under 21 CFR Parts 210/211, register annually with the FDA, report adverse events under 21 CFR 310.305, and submit to routine FDA inspection.
The compliance gap is significant. FDA’s Insanitary Conditions at Compounding Facilities guidance warns that “drugs produced under insanitary conditions… may be contaminated with filth or rendered injurious to health,” and in its most recent annual report to Congress under the Compounding Quality Act, FDA documented 42 inspections of 503B outsourcing facilities in FY2025, of which 17 were reinspections triggered by noncompliance identified in prior inspections.
Two things that number does not mean: the 17 reinspections are a subset of the 42, not an addition to it, and 17 reinspections is not 17 facilities, since one facility can be reinspected more than once.
Other key differences:
Interstate shipping: under 21 U.S.C. § 353a(b)(3)(B), a 503A pharmacy’s out-of-state distribution is capped at 5% of total prescription orders only where the state has not entered an MOU with FDA. States that have signed the MOU are treated differently. 503B facilities ship nationwide once registered.
Beyond-use dates (BUDs): far shorter for 503A under USP 797; 503B facilities can support longer dating with stability data.
Labeling: 503B products must carry “This is a compounded drug” plus lot and expiry information. 503A labels are prescription-specific.
Reporting: 503B facilities submit product reports to FDA twice yearly.
Copies of commercial drugs: both categories are prohibited from compounding essentially-copies of commercially available products, with narrow exceptions.
The 2023 USP 797 revision further tightened sterile compounding requirements for 503A pharmacies, reshaping how many smaller operations handle high-risk preparations.
Who can purchase from a 503A pharmacy versus a 503B outsourcing facility?
Only patients, via a prescriber’s patient-specific prescription, can receive medication from a 503A pharmacy. 503B outsourcing facilities can sell directly to healthcare facilities (clinics, hospitals, surgery centers) for in-office administration without naming an individual patient.
The buyer flow looks different on each side:
503A: prescriber → patient-specific Rx → pharmacy → patient (or prescriber’s office for that named patient).
503B: facility purchase order → outsourcing facility → office stock used for any patient treated on-site.
This distinction matters for the entire specialty clinic economy. Hospitals and outpatient facilities increasingly rely on outsourcing facilities for sterile, non-patient-specific preparations: in a 2019 HHS Office of Inspector General survey of Medicare-participating hospitals, 89% of those that purchased compounded drugs from outside compounders obtained them exclusively from FDA-registered outsourcing facilities, with nearly all (approximately 98%) relying on 503Bs to at least some degree. The post-DQSA framework deliberately created this category of compounders, able to produce sterile drugs at the scale hospitals and clinics need while remaining under federal CGMP oversight.
Practical clinic implications:
Weight-loss, hormone, aesthetic, and IV-therapy clinics typically combine both channels: 503A for custom-dose patient prescriptions, 503B for in-office stock like injectables and crash-cart staples.
Cross-state shipping: 503B can ship nationally; 503A is constrained by state law and the MOU status of its state.
Billing: 503B products often carry NDCs more readily, which affects reimbursement and 340B workflows.
For deeper context on how these supply channels are reshaping specialty prescribing, see 503B pharmacies are rewriting the rules of specialty prescribing and what to do when 503B GLP-1 supply gets cut off.
How VITL helps clinics manage both 503A and 503B sourcing
Most specialty clinics need both channels: 503A for patient-specific custom formulas, 503B for office-use stock; and they end up juggling separate portals, logins, and pricing sheets for each pharmacy relationship. That’s the workflow problem VITL was built to remove.
VITL consolidates ordering across vetted 503A compounding pharmacies and FDA-registered 503B outsourcing facilities in a single dashboard. Clinicians can compare pricing, place patient-specific prescriptions, batch-order office stock, and track fulfillment from one place, without changing the pharmacy relationships they already trust. Multi-location clinics get location-specific controls and compliance reporting in the same view.
If your prescribing software still treats 503A and 503B sourcing as the same workflow, that’s a problem worth a closer look, start with why your prescribing software doesn’t understand 503B pharmacies.
Reviewed by the VITL clinical operations team, which manages ePrescribing workflows across a network of both 503A compounding pharmacies and FDA-registered 503B outsourcing facilities.
Sources
FDA, Compounding and the FDA: Questions and Answers
FDA, Registered Outsourcing Facilities (count as of August 4, 2026)
21 U.S.C. § 353a and § 353b, Federal Food, Drug, and Cosmetic Act
USP 797 Pharmaceutical Compounding, Sterile Preparations (2023 revision)
U.S. Department of Health and Human Services, Office of Inspector General, Most Hospitals Obtain Compounded Drugs From Outsourcing Facilities, Which Must Meet FDA Quality Standards
U.S. Food and Drug Administration, Annual Report to Congress: Compounding Quality Act, FY 2025, pp. 9–10
